

# TRANSMITTAL FORM

(This form is to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/644,548
Filing Date	August 20, 2003
First Named Inventor	Vivien Chan
Art Unit	1646
Examiner Name	Eileen B. O'Hara
Attorney Docket Number	59516-159

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
<b>Remarks</b>		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Davis Wright Tremaine LLP		
Signature			
Printed Name	Jane E. R. Potter		
Date	October 3, 2006	Reg. No.	33,332

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	
Typed or printed name	Sharon Sheridan
Date	October 3, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/3/06  
Date

  
Sharon Sheridan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Vivien Chan et al.  
Application No. : 10/644,548  
Filed : August 20, 2003  
For : Notch Receptor Ligands and Uses Thereof  
Art Unit : 1646  
Docket No. : 59516-159  
Examiner : Eileen B. O'Hara  
Date : October 3, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/641,612, filed August 17, 2000. The references listed on the attached form PTO/SB/08 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application, with the exception of Accession No. Y11895, which is enclosed. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such


reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

DAVIS WRIGHT TREMAINE LLP

By   
Jane E. R. Potter  
Registration No. 33,332

2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Phone: (206) 628-7650  
Facsimile: (206) 628-7699



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 4

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>			
		<b>Complete if Known</b>	
		<i>Application Number</i>	10/644,548
		<i>Filing Date</i>	August 20, 2003
		<i>First Named Inventor</i>	Vivien Chan
		<i>Art Unit</i>	1646
		<i>Examiner Name</i>	Eileen B. O'Hara
		<i>Attorney Docket Number</i>	59516-159
Sheet	1	of	4

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

**Complete if Known**

Application Number	10/644,548
Filing Date	August 20, 2003
First Named Inventor	Vivien Chan
Art Unit	1646
Examiner Name	Eileen B. O'Hara

Attorney Docket Number 59516-159

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		TONON et al., t(11:19)(q21;p13) Translocation in Mucoepidermoid Carcinoma Creates a Novel Fusion Product That Disrupts a Notch Signaling Pathway, <i>Nat. Genet.</i> , 33:208-213, 2003.	
		AITKENHEAD et al., Identification of Endothelial Cell Genes Expressed in an In Vitro Model of Angiogenesis: Induction of ESM-1, $\beta$ ig-h3, and NrCAM, <i>Microvascular Res.</i> , 63:159-171, 2002.	
		LEONG et al., Activitated Notch-4 Inhibits Angiogenesis: Role of $\beta$ 1-Integrin Activation, <i>Mol. Cell. Biol.</i> , 22:2830-2841, 2002.	
		CALLAHAN et al., Notch Signaling in Mammary Gland Tumorigenesis, <i>J. Mammary Gland Biol. Neoplasia</i> , 6:23-36, 2001.	
		Genbank Accession No. AL078605, April 29, 2000.	
		RADTKE et al., Deficient T Cell Fate Specification in Mice With an Induced Inactivation of Notch1, <i>Immunity</i> 10(5):547-558, May 1999.	
		XUE et al., Embryonic Lethality and Vascular Defects in Mice Lacking the Notch Ligand Jagged1, <i>Hum. Mol. Gen.</i> 8(5):723-730, May 1999.	
		ZECCHINI et al., An Activity of Notch Regulates JNK Signalling and Affects Dorsal Closure in <i>Drosophila</i> , <i>Current Biology</i> 9(9):460-469, April 21, 1999.	
		Abstract of JP11299493, esp@cenet database, November 2, 1999.	
		Accession No. Y11895, March 14, 1997.	
		Derwent dgene database, Accession No. AAX16303, April 22, 1999.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/644,548
(Use as many sheets as necessary)				Filing Date	August 20, 2003
				First Named Inventor	Vivien Chan
				Art Unit	1646
				Examiner Name	Eileen B. O'Hara
Sheet	3	of	4	Attorney Docket Number	59516-159

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		GRAY et al., Human Ligands of the Notch Receptor, <i>Am J Pathol.</i> 154(3):785-794, March 1999.		
		LENDALH, A Growing Family of Notch Ligands, <i>BioEssays</i> 20(2):103-107, February 1998.		
		SALLOWAY et al., CADASIL Syndrome: A Genetic Form of Vascular Dementia, <i>J. Geriatr. Psychiatry Neurol.</i> 11(2):71-77, Summer 1998.		
		Genbank Accession No. AB013440, October 9, 1998.		
		BOULTER et al., DatabaseGenEmbl, Accession No. AF084576, August 30, 1998.		
		Database EST, Accession No. AI089793, October 1, 1998.		
		DUNWOODIE et al., Mouse D113: A Novel Divergent Delta Gene Which May Complement the Function of Other Delta Homologues During Early Pattern Formation in the Mouse Embryo, <i>Development</i> 124(16):3065-3076, August 1997.		
		JOUTEL et al., Strong Clustering and Stereotyped Nature of Notch3 Mutations in CADASIL Patients, <i>Lancet</i> 350(9090):1511-1515, November 22, 1997.		
		LI et al., Alagille Syndrome is Caused by Mutations in Human Jagged1, Which Encodes a Ligand for Notch1, <i>Nature Genetics</i> 16(3):243-251, July 1997.		
		MAGOVERN et al., Regional Angiogenesis Induced in Nonischemic Tissue by an Adenoviral Vector Expressing Vascular Endothelial Growth Factor, <i>Human Gene Therapy</i> 8:215-227, January 20, 1997.		
		ODA et al., Mutations in the Human Jagged1 Gene are Responsible for Alagille Syndrome, <i>Nature Genetics</i> 16(3):235-242, July 1997.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known	
Application Number	10/644,548
Filing Date	August 20, 2003
First Named Inventor	Vivien Chan
Art Unit	1646
Examiner Name	Eileen B. O'Hara
Attorney Docket Number	59516-159

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SHIRAYOSHI, Proto-Oncogene of INT-3, A Mouse Notch Homologue, Is Expressed in Endothelial Cells During Early Embryogenesis, <i>Genes to Cells</i> 2(3):213-224, March 1997.	
		UYTTENDAELE, Notch4/int-3, A Mammary Proto-Oncogene, Is an Endothelial Cell-Specific Mammalian Notch Gene, <i>Development</i> 122(7):2251-2259, July 1996.	
		ZIMRIN et al., An Antisense Oligonucleotide to the Notch Ligand Jagged Enhances Fibroblast Growth Factor-Induced Angiogenesis in Vitro, <i>Jour. Biol. Chem.</i> 271(51):32499-32502, December 20, 1996.	
		FITZGERALD et al., Interchangeability of Caenorhabditis Elegans DSL Proteins and Intrinsic Signalling Activity of Their Extracellular Domains in Vivo, <i>Development</i> 121(12):4275-4282, December 1995.	
		Genbank Accession No. Z48825, March 30, 1995.	
		ELLISEN et al., TAN-1, The Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms, <i>Cell</i> 66(4):649-661, August 23, 1991.	
		MONTESANO et al., Tumor-Promoting Phorbol Esters Induce Angiogenesis in Vitro, <i>Cell</i> 42(2):469-477, September 1985.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.